Spain's Probitas Pharma has pulled its €413m flotation after international investors shunned the issue. It is the second European biotechnology firm to cancel an initial public offering in the past few weeks.

A spokesman for Probitas said: "The company had set aside 65% of the offer for international institutional investors but that tranche was not fully covered. Also the markets have been down in the last few weeks."